DSIP — delta sleep-inducing peptide — is unusual among the peptides discussed by the research community because it was named after an effect, not a target. In 1977 a group working on humoral sleep factors isolated a nonapeptide from rabbit brain that produced slow-wave (delta) EEG activity on infusion, and called it delta sleep-inducing peptide accordingly [1]. Nearly five decades later, the human data on that effect amounts to a small number of studies, most of them published between 1977 and the early 1990s, none adequately powered by contemporary standards, and none systematically replicated. This explainer sets out what that literature does and does not support.
01 What DSIP is
DSIP is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. It was identified from rabbit cerebral tissue by Schoenenberger and Monnier, who were pursuing the hypothesis that sleep is at least partly transmitted by circulating humoral factors rather than being orchestrated entirely within the central nervous system [1]. A peptide that appeared to transfer a sleep-like state would have been a significant neurobiological finding, which is why the discovery attracted real attention through the 1970s and 1980s.
Two structural facts are important for anyone reading the later literature. First, DSIP is very short and hydrophilic for a neuroactive peptide, and no specific DSIP receptor has ever been identified — the mechanisms proposed for its effects have remained speculative [6]. Second, DSIP is not a licensed medicine anywhere, and it is not a controlled drug in the UK. All published work is research-context only.
02 The discovery and animal literature
The foundational characterisation reported that the isolated nonapeptide enhanced delta-wave EEG activity in animals, and the isolation chemistry was described in detail in the original reports [1]. Subsequent rodent work explored sleep effects and other actions, including a 2021 study reporting that a DSIP-like peptide reduced cerebral infarction in mice and myocardial infarction in rats when given during reperfusion [9], and a 2018 study reporting that a phosphorylated DSIP analogue restored spatial memory and p-CREB expression in a high-altitude model [10].
These findings are worth stating precisely for what they are: preclinical, in animals, often using analogues rather than native DSIP, and not replicated as clinical effect in humans. They do not establish that DSIP produces sleep, neuroprotection, or any other outcome in people.
03 The human sleep trials
The human sleep literature is small and grounded in a series of studies by Schneider-Helmert and colleagues. The most frequently cited is the 1981 report in Experientia, which tested synthetic DSIP by acute intravenous infusion in a small group of middle-aged chronic insomniacs [2]. The published abstract describes longer sleep duration, a higher reported quality of sleep with fewer interruptions, and slightly more REM sleep, with no daytime sedation reported, and a sleep-promoting effect that appeared only in the second hour after infusion [2]. The sample was very small (single-digit numbers of participants), the dose was fixed by body weight, and there was no registered or pre-specified endpoint.
Further reports by the same group followed across the 1980s, including a 1986 paper on DSIP in sleep disturbances [3] and a 1987 double-blind study in chronic insomniac patients [4]. An independent group published a small single-blind crossover in the mid-1980s examining acute and delayed effects on sleep EEG parameters [5]. When the field was reviewed more broadly — for example in the 1997 review of neuropeptides and human sleep [7] — the collated signal was described as modest and inconsistent rather than established.
Three points matter for interpretation:
- No adequately powered trial. Every human sleep study is small, typically single-digit to low-double-digit participants, and designs are mixed (open, single-blind crossover, one small double-blind study). Studies of this size can only detect large effects, and a null result in such a study proves almost nothing in either direction.
- No replication to modern standards. No study with pre-registered endpoints, polysomnography-led primary outcomes, and independent multi-site replication has been published. The publication record essentially stops after the early 1990s.
- No systematic review. There is no pooled meta-analysis of DSIP for any indication, because the studies are too small, too heterogeneous, and too old to pool credibly.
04 The non-sleep human literature
Beyond sleep, the human DSIP record is thin and mostly observational. A small open-label study published in 1998 examined DSIP in opioid detoxification and reported results without a placebo control [8]. Russian and Eastern European groups through the 1990s reported effects on stress response and on withdrawal syndromes, largely in uncontrolled series. None of this work constitutes controlled evidence of efficacy for any indication, and the compound was never developed to marketing authorisation.
The honest summary is that DSIP attracted genuine scientific interest for roughly fifteen years and then largely stopped being studied in humans, at the same time as better-characterised hypnotics came to market.
05 Why the evidence stalls
Three structural problems explain the state of the literature. First, the proposed mechanism was never resolved: without an identified receptor or a clearly characterised signalling pathway, it is difficult to design targeted pharmacology or to distinguish a real effect from a nonspecific one [6]. Second, dosimetry and delivery were inconsistent between studies, and the peptide's short half-life and blood-brain-barrier behaviour were never fully pinned down. Third, and most importantly, the small effect sizes plausibly detectable in tiny crossover designs sit close to the threshold of measurement noise, so isolated positive findings are difficult to separate from chance.
In our grading framework this is the archetypal Limited evidence situation: a genuine but small and dated body of human work, a plausible but unproven mechanism, and no replication.
06 Regulatory position in the UK
DSIP has no marketing authorisation from the MHRA or any other major regulator, and it is not listed as a controlled drug under the Misuse of Drugs Act 1971. It may therefore be encountered as a research chemical marketed "for research use only". Under the Human Medicines Regulations 2012, a product intended for human use and presented for medicinal purposes is a medicinal product and requires a licence before it can be supplied; the "research use only" framing is a statement of intended purpose, not a route around medicines regulation. Researchers should note that the MHRA has tightened its guidance on the labelling of research peptides in the UK [11].
This section is a description of the current regulatory landscape for research context, not legal advice, and it is not a commentary on whether DSIP should be used by anyone.
07 How we grade DSIP
We grade DSIP Limited for any human sleep or performance claim. The grade reflects the following: a defined chemical entity with a described discovery history; a small number of dated human studies with at least one double-blind design; a consistent absence of replication, of a defined receptor, of a systematic review, and of any regulatory evaluation; and a matching body of preclinical work that has not translated into controlled human data. A Limited grade is not a statement that DSIP does nothing. It is a statement that the published evidence cannot tell us whether it does, which is a materially different position from one supported by replicated trials.
08 What would change the grade
A pre-registered, adequately powered, placebo-controlled trial with polysomnography-led endpoints would raise the grade. So would independent replication of any of the historical findings, or identification and pharmacological characterisation of a specific DSIP receptor. Absent those, the position is likely to remain where the field left it in the early 1990s.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.